[PDF][PDF] Acquired resistance to immune checkpoint inhibitors
AJ Schoenfeld, MD Hellmann - Cancer cell, 2020 - cell.com
Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple
tumor types, providing unprecedented survival in some patients. Despite the characteristic …
tumor types, providing unprecedented survival in some patients. Despite the characteristic …
[HTML][HTML] 'Stem-like' precursors are the fount to sustain persistent CD8+ T cell responses
D Zehn, R Thimme, E Lugli, GP de Almeida… - Nature …, 2022 - nature.com
Virus-specific CD8+ T cells that differentiate in the context of resolved versus persisting
infections exhibit divergent phenotypic and functional characteristics, which suggests that …
infections exhibit divergent phenotypic and functional characteristics, which suggests that …
[PDF][PDF] The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes
Q Huang, X Wu, Z Wang, X Chen, L Wang, Y Lu… - Cell, 2022 - cell.com
Summary Blocking PD-1/PD-L1 signaling transforms cancer therapy and is assumed to
unleash exhausted tumor-reactive CD8+ T cells in the tumor microenvironment (TME) …
unleash exhausted tumor-reactive CD8+ T cells in the tumor microenvironment (TME) …
[PDF][PDF] Coupled scRNA-seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer
Cell function and activity are regulated through integration of signaling, epigenetic,
transcriptional, and metabolic pathways. Here, we introduce INs-seq, an integrated …
transcriptional, and metabolic pathways. Here, we introduce INs-seq, an integrated …
[PDF][PDF] Intratumoral Tcf1+ PD-1+ CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy
I Siddiqui, K Schaeuble, V Chennupati, SAF Marraco… - Immunity, 2019 - cell.com
Checkpoint blockade mediates a proliferative response of tumor-infiltrating CD8+ T
lymphocytes (TILs). The origin of this response has remained elusive because chronic …
lymphocytes (TILs). The origin of this response has remained elusive because chronic …
[PDF][PDF] Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
[PDF][PDF] Defining T cell states associated with response to checkpoint immunotherapy in melanoma
Treatment of cancer has been revolutionized by immune checkpoint blockade therapies.
Despite the high rate of response in advanced melanoma, the majority of patients succumb …
Despite the high rate of response in advanced melanoma, the majority of patients succumb …
Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade
N Budimir, GD Thomas, JS Dolina… - Cancer immunology …, 2022 - AACR
Abstract Anti–PD-1/PD-L1 immune checkpoint blockade (ICB) therapy has revolutionized
the treatment of many types of cancer over the past decade. The initial therapeutic …
the treatment of many types of cancer over the past decade. The initial therapeutic …
[HTML][HTML] TCF1 in T cell immunity: a broadened frontier
TCF1 and its homologue LEF1 are historically known as effector transcription factors
downstream of the WNT signalling pathway and are essential for early T cell development …
downstream of the WNT signalling pathway and are essential for early T cell development …
[PDF][PDF] T cell dysfunction in cancer
DS Thommen, TN Schumacher - Cancer cell, 2018 - cell.com
Therapeutic reinvigoration of tumor-specific T cells has greatly improved clinical outcome in
cancer. Nevertheless, many patients still do not achieve durable benefit. Recent evidence …
cancer. Nevertheless, many patients still do not achieve durable benefit. Recent evidence …